Besides activating NFkB by phosphorylating IkBs, IKKa/IKKb kinases are also involved in regulating metabolic insulin signaling, the mTOR pathway, Wnt signaling, and autophagy. How IKKb enzymatic activity is targeted to stimulus-specific substrates has remained unclear. We show here that NEMO, known to be essential for IKKb activation by inflammatory stimuli, is also a specificity factor that directs IKKb activity toward IkBa. Physical interaction and functional competition studies with mutant NEMO and IkB proteins indicate that NEMO functions as a scaffold to recruit IkBa to IKKb. Interestingly, expression of NEMO mutants that allow for IKKb activation by the cytokine IL-1, but fail to recruit IkBs, results in hyperphosphorylation of alternative IKKb substrates. Furthermore IKK's function in autophagy, which is independent of NFkB, is significantly enhanced without NEMO as IkB scaffold. Our work establishes a role for scaffolds such as NEMO in determining stimulus-specific signal transduction via the pleiotropic signaling hub IKK.
INTRODUCTION
Reliable cellular signal transduction depends on the specificity of kinases. Unlike some metabolic enzymes, in which the catalytic site may show great specificity for particular small molecule substrates, protein kinases require specificity domains. When such specificity domains are encoded by distinct specificity factors, the kinase activity can in principle be directed to alternate specific substrates, allowing for functional pleiotropy (Bhattacharyya et al., 2006; Ubersax and Ferrell, 2007) . One may distinguish between catalytic (or ''allosteric'') specificity factors, that alter the intrinsic catalytic activity of the kinase toward a specific substrate, and scaffold (or ''tethering'') specificity factors, that enhance otherwise weak interactions between substrate and kinase (Burack and Shaw, 2000) . Whereas the c-Jun N-terminal kinase (JNK)-interacting protein (JIP1), the JNK/SAPK-activating protein 1 (JSAP1), and the kinase suppressor of Ras (KSR) are thought to be in the former category, the axin scaffolding proteins target the pleiotropic kinases GSK3 and CK1 to the b-catenin pathway (Burack and Shaw, 2000; Wu and Pan, 2010; Amit et al., 2002) , and the Ste5 scaffold directs the specificity of yeast MAPK signaling (Schwartz and Madhani, 2004; van Drogen and Peter, 2002) . Indeed, shuffling of binding pockets of Ste5 by site-directed mutagenesis enables redirection of signaling specificity (Dueber et al., 2003) . Thus, multivalent scaffold proteins may not only direct kinase substrate specificity but also ensure signaling specificity of a pleiotropic kinase by coordinating upstream and downstream signaling axes.
The IkB kinase (IKK) complex is ubiquitously expressed and functionally pleiotropic (Hayden and Ghosh, 2008; Scheidereit, 2006) . Its major catalytic component, IKKb (also known as IKK2), was purified as the IkB kinase that controls nuclear translocation of NFkB to initiate proinflammatory gene transcription by phosphorylating the canonical IkBs, IkBa, IkBb, and IkBε (Hayden and Ghosh, 2008; Hoffmann and Baltimore, 2006; Scheidereit, 2006) . However, recent literature suggests that IKKb also plays critical roles in many other biological processes, including autophagy, insulin signaling, and DNA damage responses, by targeting diverse alternative cellular substrates for phosphorylation ( Figure 1A ) (reviewed in Chariot [2009] and Scheidereit [2006] ).
The large number of substrates, and the diverse biological functions regulated by their phosphorylation raise the question of whether IKKb enzymatic activity may be targeted to distinct substrates. To ensure fidelity as a signal transducer of diverse signals, one would expect the activation of the kinase by upstream pathways to be coordinated with downstream substrate selection.
RESULTS

Constitutively Active IKKb Requires NEMO for NFkB Activation
In response to the inflammatory cytokine IL-1 IKKb rapidly phosphorylates S32/36 of IkBa, thereby triggering its ubiquitindependent proteasomal degradation, while phosphorylation of the NFkB subunit p65 occurs with delayed kinetics (Figures 1B and S1A) . However, using purified, constitutively active IKKb (HA-IKKbEE) in an in vitro kinase assay, we find high phosphorylation of both IkBa and p65 proteins with no preference for IkBa ( Figure 1C ) suggesting that in vivo IKKb's preference for IkB phosphorylation is regulated by additional factors. In vivo, IKKb activation in response to inflammatory cytokine and pathogenassociated molecular patterns (PAMPs) stimulation requires NEMO, which connects the kinase complex to ubiquitin chains emanating from receptor-associated signaling complexes (Israë l, 2010) . To test whether NEMO may also be determining the target specificity of the catalytic enzyme, we used a constitutively active form of IKKb generated through mutation of the critical activation loop serines 177 and 181 to phosphomimetic glutamates (IKKbEE). Retroviral transduction of wild-type fibroblasts with IKKbEE resulted in the expected increase in steady-state NFkB activity, but similar expression of IKKbEE in NEMO-deficient cells had only a modest effect ( Figure 1D ). However, reconstitution with retrovirally expressed NEMO restored the strong NFkB DNA binding activity. Strikingly, in vitro kinase assays with immunoprecipitated IKK using either FL-IkBa ( Figure 1D ) or GST-IkBa 1-54 ( Figure S1B ) as substrate showed that NEMO did not alter the catalytic IKK activity in these cells, suggesting that it has a specific role in the NFkB activation pathway at a step downstream of its known function in IKK activation. Indeed, we found that IKKbEE caused only weak IkBa phosphorylation and degradation in unstimulated NEMO-deficient cells, unless NEMO was reconstituted ( Figure 1E ). Taken together these data indicate that intrinsic substrate specificity of IKKb is not sufficient for efficient IkB phosphorylation, but that NEMO plays a role in targeting IKK activity toward the IkB-NFkB signaling module.
The ZF of NEMO Is Required for Efficient Phosphorylation of IkBa NEMO's N-terminal region interacts with IKKb, and the central CoZi-region allows for dimerization and binding to linear and K63 polyubiquitin chains, connecting IKK to inflammatory receptor pathways (Figure 2A ) (Israë l, 2010) . A frameshift mutation that completely removes NEMO's C-terminal Zinc finger (ZF) causes incontinentia pigmenti; its molecular function however remains unclear (Makris et al., 2002) . While it is critical for NFkB activation triggered by genotoxic stress (Huang et al., 2002) , its role in inflammation-induced NFkB activation is celland stimulus-specific. Disruption of the ZF was found to prevent TNF-but not IL-1b-induced NFkB activation in MEFs (Makris et al., 2002) . A complete defect in cytokine-induced NFkB activation was observed in human T cells expressing human C417R NEMO (corresponding to C410R in mouse NEMO) (Yang et al., 2004) , while NFkB activation by LPS was normal in mouse B cells expressing this mutant (Huang et al., 2002) . More recently the ZF has been implicated in enhancing the affinity of NEMO for binding to K63 linked polyubiquitin chains, important for IKK activation by specific stimuli (Laplantine et al., 2009) . We examined the possible role of the NEMO ZF on NFkB activation in the context of constitutively active IKKb. We generated a truncation (DC25), a debilitating (C389/393S), and a neutral (M408S) mutant of the ZF domain. Reconstitution of NEMO-deficient cells with these constructs resulted in expression levels comparable to those in wild-type MEFs (Figure S2A ). In cells expressing either WT or the M408S NEMO, which does not affect the overall structure of the ZF, strong NFkB activity was detected ( Figure 2B ), while only modest Figure 1 . Constitutively Active IKKb Is Not Sufficient for NFkB Activation, but Requires NEMO (A) IKK is a pleiotroptic transducer capable of phosphorylating many substrates involved in different biological functions. IKKb phosphorylates the tumor suppressor p53 at S362 and S366 to regulate its stability (Xia et al., 2009) , the insulin Receptor (IR) substrate 1 (IRS-1) at S307 resulting in the termination of metabolic insulin signaling (Gao et al., 2002) , the tumor suppressor Tuberous sclerosis 1 (TSC1) at S487 and S511 to activate the mTOR pathway, enhance angiogenesis and tumor development (Lee et al., 2007) , b-catenin, a key molecule in Wnt signaling, as well as FOXO3a which acts downstream of growth factor signaling (PI3K/Akt) (Lamberti et al., 2001) . Induction of autophagy depends on IKKb kinase activity; the relevant substrates remain to be identified (Comb et al., 2011; Criollo et al., 2010) . (B) Phosphorylation of IkBa (S32/36) and p65 (S536) was measured in fibroblasts upon stimulation with 1 ng/ml IL-1b. nuclear NFkB activity was observed in NEMO-deficient cells. Strikingly, truncating and debilitating the ZF abolished NEMO's ability to reduce IkBa levels (as well as IkBb and IkBε, Figure S2B ) and to enhance NFkB activity in the presence of IKKbEE (Figure 2B ). These data suggest that the ZF of NEMO is critical for the active IKK complex to efficiently target IkBs for degradation in vivo, to allow for NFkB activation, even though ZF mutations had no effect on in vitro IKK kinase activity ( Figure S2C ).
To examine NEMO's role in targeting IKK toward IkBs during inflammatory signaling, we had to identify conditions in which NEMO mutants, defective in IkB targeting, allowed for efficient IKK activation. NEMO-deficient cells reconstituted with NEMO mutants were exposed to TNF, IL-1b, and LPS. In cells expressing WT NEMO and M408S mutant NEMO, all stimuli induced in vitro kinase activity, although kinase activity induced by TNF was attenuated in M408S NEMO-expressing cells ( Figures 2C,  S2D , and S2E). IL-1b and LPS also induced strong, yet somewhat weaker kinase activity in cells expressing NEMO with a truncated or debilitated ZF ( Figures 2C and S2D ), though both mutants were defective in supporting TNFa-induced kinase activity (Figure S2E) , consistent with data reported by Makris et al. (2002) . Thus, the ZF of NEMO appears to be largely dispensable for the activation of the IKK complex by IL-1b and LPS in fibroblasts, reflecting stimulus-specific requirements for IKK activation.
If the ZF were necessary for recruiting the IKK complex to IkBs, a defect in IkBa phosphorylation and degradation and subsequent NFkB activation in cells expressing ZF-mutated NEMO would be anticipated. As expected, in NEMO À/À cells expressing WT NEMO or a neutral M408S mutant, phosphorylation and degradation of IkBa were induced by IL-1b ( Figure 2D ). However, in cells expressing NEMO with a truncated or debilitated ZF, IL-1b stimulation triggered neither IkBa phosphorylation nor degradation. Furthermore, NFkB DNA binding activity induced by IL-1b, LPS, and TNF was defective with ZF mutants while it was strongly activated in WT and M408S-expressing cells ( Figures 2E, S2F , and S2G). The reduction in kinase activity measured in cells expressing truncated or C389/93S NEMO could not account for the observed defect in NFkB activation, as similarly low kinase activities in WT cells (elicited by lower stimulus concentrations) allowed for detection of strong NFkB DNA binding ability (Figure S2H) . These data are consistent with results obtained with constitutively active IKKb and further indicate that NEMO does indeed play a role in NFkB activation that is distinct from its function in activating the IKK complex, most likely by facilitating the recruitment of IkBs to the IKK complex.
NEMO Forms a Complex with IKKb and IkBa
NEMO's apparent role as a specificity factor for IKK may be mediated by allostery altering the catalytic specificity of the enzyme or by functioning as a scaffold tethering IkB substrates toward the catalytic site. Given that in vitro kinase assays did not reveal differences in catalytic activity, we hypothesized that NEMO functions as a recruitment scaffold by enhancing the IKK-IkB interaction through an N-terminal interaction with IKKb and a C-terminal interaction with IkBa ( Figure 3A ). To test this hypothesis, IkBa was immunoprecipitated and its interaction with IKKb and NEMO was analyzed by immunoblotting (Figure 3B) . A strong interaction between IkB and IKK could be detected in the presence of WT NEMO, but not in its absence. Deletion of the ZF abolished binding. The interaction was dependent on IKKb, as the interaction of IkB with WT NEMO was reduced in the absence of IKKb or when an N-terminally truncated NEMO, which lacks the IKKb binding site, was used.
Comparable results were obtained when NEMO was immunoprecipitated ( Figure S3 ). Together, these data indicate that NEMO interacts with IkBa, that the ZF is required for this interaction, and that the interaction is strengthened in the presence of IKKb, suggesting the existence of a IkB:IKK:NEMO complex. In a functional assay, in which steady-state expression of IkBa was analyzed in the presence of small amounts of IKKbEE, reduced levels of IkBa could only be detected when WT NEMO was cotransfected, but not when N-and C-terminally truncated NEMO was expressed, further suggesting that NEMO indeed enhances IkBa turnover by means of complex formation with IkBa and IKKb ( Figure 3C ).
The N-terminal 54 amino acids of IkBa are known to be sufficient for phosphorylation by IKKb ( Figure 3D ) (Wu and Ghosh, 2003) . As NEMO appears to be important for targeting IKKb to IkBa, IkBb, and IkBε, we hypothesized that a region conserved in canonical IkBs would mediate the interaction with NEMO. Most mutations of conserved residues in IkBa showed no defects in phosphorylation and degradation upon stimulation with IL-1b (data not shown). However, mutation of negatively charged residues D27 and D28 (corresponding to D14 and E15 in IkBb) to positively charged arginines resulted in a strong reduction of inducible phosphorylation and degradation upon stimulation with IL-1b ( Figure 3E ), indicating that these amino acids are critical for phosphorylation by IKKb in cells. IKKbEEinduced phosphorylation of both the full-length and 1-54 IkB D27/28R mutants was comparable with WT IkBa in in vitro kinase assays ( Figure 3F ), indicating that the consensus phosphorylation site for IKKb was not disrupted by the mutation. Instead, the in vivo defect in phosphorylation may be due to impaired recruitment by NEMO as the D27/28R IkBa mutation weakened IkBa's interaction with NEMO and IKK2 ( Figure 3G ). Together, these data indicate that in cells, NEMO forms a complex with IkBa and IKKb and that amino acids D27 and D28 in the N terminus of IkBa are critical for complex formation.
To test the interaction between NEMO and IkBa more directly, we produced highly purified recombinant, bacterially expressed NEMO and IkBa and performed gel filtration analysis. As shown in Figure 3H , free IkBa was detected in the low molecular weight fractions 26-35. In the presence of full-length NEMO IkBa was also present in NEMO-containing high molecular weight fractions (13-18). In contrast, no change in the elution profile of IkBa was detected in the presence of a C-terminal NEMO deletion mutant (lower panel). These data are indicative of a direct interaction between NEMO and IkBa that depends on NEMO's C terminus.
NEMO Functions as a Scaffold for IKKb
A hallmark of scaffold proteins is a nonmonotonic dose response curve: increasing amounts of scaffold allow for increased complex formation, but when the scaffold concentration exceeds that of the kinase or substrate whose interaction it coordinates, then the excess will inhibit the formation of the full complex, by instead favoring the formation of many incomplete subcomplexes, an effect referred to as ''combinatorial inhibition'' (Ferrell, 2000; Levchenko et al., 2000) . Accordingly, computational simulations of a mathematical model for the formation of the IkB-NEMO-IKK complex (Supplemental Experimental Procedures) showed increased complex formation when NEMO amounts are increased within a substoichiometric regime, but reduced functional complexes within a higher regime ( Figure 4A ). To test this experimentally, we transfected 293T cells with increasing amounts of NEMO and limiting amounts of IKKbEE. Expression of small to intermediate amounts of NEMO led to a dose-dependent increase of IkB phosphorylation and reduced levels of total IkBa expression ( Figure 4B and quantification Figure 4C ) caused by intrinsic IKKbEE activity. Strikingly, high overexpression resulted in reduced phosphorylation of IkBa and increased IkBa levels. Expression of NEMO mutants that only interacted with either IKKb (NEMO DC25) or IkBa (NEMO DN) had no effect. The kinase activity, assayed in vitro, remained unchanged throughout all NEMO expression levels ( Figures 4D  and S4 ). Thus, in the context of physical interactions delineated in Figures 3B-3H , the functional characteristics described in Figures 4A and 4B support the conclusion that NEMO functions as a specificity scaffold that recruits classical IkBs to IKK.
Throughout these studies of NEMO's role as a specificity factor in vivo, we failed to observe such a function in vitro. We considered the explanation that the substrate availability/ concentration in cells is lower than in in vitro kinase assay reaction conditions, in which substrate is supplied in excess to ensure sensitivity and linear dose responses. To test this hypothesis we attempted to mimic in vivo conditions by performing the kinase reaction in the presence of high concentrations of nonspecific competitor protein (BSA) and limiting concentrations of substrate. Using these conditions, IkBa phosphorylation was stronger and occurred with faster kinetics in the presence than in the absence of NEMO ( Figure 4E ). In contrast, ZF-deleted NEMO failed to enhance IkBa phosphorylation. Similarly NEMO had no effect on phosphorylation of IkBa DR, which is phosphorylation defective in vivo. These data further support the notion that NEMO acts as a scaffold for IKKb likely by enhancing the local concentration of IkB to allow for its more efficient phosphorylation.
NEMO Directs IKKb Activity Away from Alternative Substrates
IKKb is a pleiotropic kinase that is known to phosphorylate numerous alternative substrates in vivo, in addition to IkBa. To analyze the potential effect of the scaffolding function of NEMO in this in vivo scenario we constructed an in silico model for IkB phosphorylation, in which IKKb can bind to and phosphorylate IkBs or alternative substrates ( Figure 5A ). Akin to our experimental results ( Figure 4E ), model simulations suggested Figure S5C ) after a 15 min kinase reaction. Phosphorylation in the absence of NEMO was set to 1. See also Figure S5 . that in the absence of alternative substrates (i.e., in vitro) the ZF-dependent NEMO scaffold function would have little effect on phosphorylation of IkB, while in their presence (i.e., in vivo), efficient phosphorylation of IkB may only occur in the presence of WT but not ZF mutant NEMO ( Figure 5B, left panel) . In contrast, NEMO's scaffolding function was predicted to restrict the phosphorylation of alternate substrates with the ZF mutant NEMO leading to the hyperphosphorylation of alternative IKKb substrates ( Figure 5B, right panel) .
To test this prediction experimentally, we analyzed steadystate phosphorylation of RelA/p65 Ser536, a well-established alternative target of IKKb. Only low levels of p65 were phosphorylated in NEMO-deficient cells, but IKKbEE expression greatly enhanced phosphorylation levels ( Figure 5C ). Strikingly, expression of WT NEMO resulted in a strong reduction of phosphorylated p65, while ZF-mutated NEMO showed similar p-p65 levels to the parental NEMO-deficient IKKbEE cells, indicating that in contrast to IkBa, p65 is a NEMO-independent substrate. Indeed, in kinase assays performed in the presence of competitor protein and limiting amounts of substrate to reflect in vivo conditions, NEMO had no effect on the phosphorylation of p65 or p105, while IkBa phosphorylation was strongly enhanced by the addition of NEMO ( Figures 5D and 5E ). In contrast, without competitor, phosphorylation of IkBa, p65, and p105 was unaffected by NEMO ( Figures 5E and S5C ). These data not only demonstrate that NEMO does not affect IKKb kinase activity per se, but that it specifically channels IKKb kinase activity to IkBa in conditions of low substrate abundance.
Next we asked whether we could observe similar substrate competition in the context of stimulated cells. As expected, IL-1b stimulation rapidly induced IkBa phosphorylation in NEMO-deficient cells reconstituted with WT NEMO, ( Figure 6A ). No IkBa phosphorylation was detectable in the presence of ZF mutant NEMO but instead alternative IKKb substrates, p65 and p105, were strongly phosphorylated. Similar results were obtained upon stimulation with LPS ( Figure S6A ). Phosphorylation of p65 and p105 was indeed caused by IKKb, as treatment with an IKKb-specific inhibitor abolished phosphorylation (Figure S6B ). Despite hyperphosphorylation of p65 and p105 we did not detect measurable levels of NFkB activity ( Figure 2E and data not shown). These data confirm that NEMO not only enhances phosphorylation of IkBs, but also restricts the phosphorylation of alternative substrates.
We next addressed the implicit hypothesis that IkB and alternative substrates are effectively competing in vivo for limited enzyme activity. Using cells that lack the IkB substrates (ikba À/À b À/À ε À/À ), phosphorylation of both p65 and p105 was strongly induced as early as 5 min post-IL-1b stimulation, while it was barely induced in WT cells ( Figure 6B ). These data suggest that NEMO's role as a specificity factor is dependent on the availability of IkB substrates, further supporting a role of NEMO in acting as a scaffold/tethering factor to direct IKK's activity specifically to IkBs. Recent studies have shown that IkBa phosphorylation and degradation are not required for IKKb-induced autophagy, suggesting the involvement of alternative IKKb substrates (Comb et al., 2011; Criollo et al., 2010) . Our model of NEMO as a specificity factor for IkBs that restricts the phosphorylation of alternative IKKb substrates would predict that autophagy may be hyperactivated in cells that express ZF-debilitated NEMO. Indeed, when ZF-deleted NEMO was expressed along with IKKbEE, the number of cells that stained positive for the autophagy marker LC3 was significantly enhanced over that of WT NEMO controls ( Figure 6C ). Concomitantly, phosphorylation of p70S6K, a marker for mTOR activity, was strongly reduced, while the upstream AMPK was hyperphosphorylated in cells expressing the ZF mutant NEMO (Figure 6D ), indicating that the signaling required for the induction of autophagy is hyperactivated by constitutively active IKKb when NEMOs IkB targeting function is lost. Similarly, starvation increased the number of LC3 positive cells harboring a ZF-deleted NEMO ( Figure 6E ), despite comparable levels of NEMO-associated IKK kinase activity ( Figure S6C ). These data further show that autophagy is hyperactivated when IKKb loses its ability to phosphorylate IkBs, but instead hyperphosphorylates alternative substrates.
DISCUSSION
We have presented several lines of evidence that NEMO plays an essential role in targeting IKK to the IkB-NFkB signaling module. Previous studies focused on NEMO's essential role in the activation of IKK via its ability to bind ubiquitin chains, which are a hallmark of inflammatory signaling by receptors of the TNFR and TLR/IL1R superfamilies. Using a constitutively active IKK variant (Figure 1 ) and identifying a specific mutation in NEMO (Figure 2 ), we were able to distinguish between these two essential functions in activation and targeting. Physical interaction studies indicated that IKK-IkB interactions are enhanced by NEMO, which interacts not only with IKK through its N terminus (May et al., 2000; Mercurio et al., 1999) but may also form a stable complex with IkBa via its C terminus (Figure 3 ). Using combined in silico kinetic modeling and in vivo experimental analysis we showed that the dose-response characteristics of NEMO are indeed consistent with bivalent interactions (Figure 4) that support a scaffolding model for NEMO. Consistent with such a model, NEMO enhances IkB phosphorylation in cells, and in in vitro conditions in which alternative substrates are abundant ( Figure 5 ). NEMO reduces alternate substrate phosphorylation ( Figure 6 ) and channels IKK activity specifically to IkBs; it therefore not only sensitizes the inflammatory pathway but may also increase its responsiveness to transient and dynamically regulated IKK signals (Cheong et al., 2006; Werner et al., 2005) .
NFkB activation occurs over a wide dynamic range. In the cyclin-dependent kinase system, alternative substrates are thought to function as competitive inhibitors for specific phosphorylation (Kim and Ferrell, 2007) . The resulting ultrasensitivity renders the pathway insensitive to weak signals and responsive only to high levels of stimulus. The role of NEMO may thus be particularly important at low levels of stimulus, as it counteracts the ultrasensitivity brought by an abundance of alternative substrates. However, when IKK is highly activated, NEMO's scaffolding function may be less critical. This may in part explain why Huang et al. (2002) did not observe a strong defect in NFkB activation in a ZF mutant B cell line in response to high doses of LPS.
We show a direct interaction between recombinant purified NEMO and IkBa ( Figure 3H ). Our coimmunoprecipitation experiments suggest that the NEMO-IkBa interaction is strengthened by IKKb (Figure 3B ), suggesting a stable ternary complex in which the N terminus of NEMO binds to IKK while its C terminus facilitates interaction with IkBa, and IKKb itself interacts with the C terminus of IkBa through its ULD-SDD domains (Xu et al., 2011) . Interestingly, this interaction appears to be important for IKK's specificity. Our data suggest that the N-terminal aspartic acids D27/28 in IkBa are also critical for the efficient phosphorylation of IkBa on S32/36 in vivo, while its ability to be phosphorylated by IKKb remains intact in vitro. Whether NEMO directly interacts with the IkBa N terminus or whether the N-terminal aspartic acids are participating in binding to IKK to form the functional ternary complex remains to be determined. However, our data support the function of NEMO as a scaffold that enhances the local concentration of IkBa to allow for its specific and rapid phosphorylation.
Our work not only adds to our understanding of NEMO's biological function, it also provides a framework for understanding IKK as a pleiotropic signal transducer that is involved in numerous biological processes and is capable of stimulusspecific phosphorylation of specific substrates. Although IKK's name suggests specificity for IkB phosphorylation, it is NEMO that determines its substrate specificity and function within the inflammatory pathway. Akin to how the yeast MAPK Ste11p mediates distinct signaling axes responsive to mating pheromone or hyperosmolarity depending on its association with scaffold proteins Ste5p or Pbs2p respectively (Engströ m et al., 2010; Schwartz and Madhani, 2004; van Drogen and Peter, 2002) , NEMO defines the inflammatory signaling axis mediated by IKK, owing to its multivalent interactions with ubiquitin chains, IKK, and IkB. We would expect that other scaffolds might be identified for IKK's alternate functions in autophagy or insulin signaling. Such scaffolds may either be similarly multivalent, capable of replacing NEMO and thus insulating the pathway from inflammatory signaling, or they may be bivalent to function with NEMO to connect IKK to other upstream activation pathways or target IKK to other downstream substrates. The latter scenarios would provide for crosstalk with the inflammatory signaling axis, which may underlie the pleiotropic functions of inflammation itself. On a related note, it is not known whether the IKK-interacting proteins RAP1 or ELKS, which are essential for phosphorylation of p65 (Teo et al., 2010) or activation by genotoxic stress , respectively, function with NEMO or in its stead. The use of scaffolds to direct IKK's target specificity constitutes a modular strategy to facilitate signaling specificity while allowing for signaling crosstalk within this regulatory hub. The DC25 NEMO mutant described here resembles NEMO expressed in some patients with incontinentia pigmenti (IP) as a result of a frameshift mutation (Makris et al., 2002) . IP is an X-linked genetic disease thought to be caused for the most part by inactivation of NFkB signaling and hypersensitivity of NEMO-deficient cells to TNF-induced apoptosis (Courtois and Israë l, 2011) . Interestingly, in IP mouse models an increase of inflammatory cytokines including TNF and IL-1b could be observed in the epidermis at the early onset of the disease (Makris et al., 2000; Nenci et al., 2006; Pasparakis et al., 2002) . Hyperactivation of autophagy reported here might provide an explanation for this disease phenotype, as autophagy has recently been implicated to positively contribute to the biogenesis and secretion of inflammatory cytokines such as IL-1b (Dupont et al., 2011) .
To harness the potential of the pleiotropic IKK signal transducer as a drug target in numerous types of inflammatory diseases, diabetes, and cancers, it is critical to understand how its activity is directed to different signaling axes and cellular functions and the degree to which these are insulated from or connected with each other. The present work identifies NEMO as a key molecule in this systems behavior and provides a framework for future investigations.
EXPERIMENTAL PROCEDURES Cell Culture and Stimulations
Immortalized NEMO-deficient MEFs were generated via the 3T3 protocol from embryos derived from NEMO À/À mice (Rudolph et al., 2000) . IkBa
cells and IkBa À/À cells were described previously (Basak et al., 2007) .
3T3 cells were reconstituted by retroviral transduction with WT or mutant pBABE.mNEMO.puro, pBABE. IkBa.puro constructs, and/or with pBABE.IKKbEE.hygro or empty vector controls. Cells were selected with puromycin Hydrochloride (Sigma) and hygromycin B (Invitrogen), respectively, and expression of the stably expressed constructs was verified by western blotting. Cells were stimulated with recombinant murine TNFa (Roche), LPS (Sigma), or murine IL-1b (R&D).
Expression and Purification of Recombinant NEMO and IkBa
His-tagged human recombinant full-length or 1-319 truncated human NEMO was cloned into pET29 expression vector. pET29.hNEMO WT or 1-319 and pET15.IkBa were transformed into BL21 cells. Expression was induced with 0.25 mM IPTG at room temperature, and upon sonication proteins were purified in a buffer containing 50 mM Tris (pH 7.5), 300 mM NaCl, 10% Glycerol, 10 mM Imidazole, 25 mM ZnSO 4 (for WT NEMO) using Ni-NTA beads. Proteins were eluted in buffer containing 250 mM Imidazole and dialyzed.
Size Exclusion Chromatography
For size exclusion chromatography individual proteins were mixed with each other at a ratio of 1:1 and incubated at room temperature for 1hr to form complexes prior to size exclusion chromatography. 150 ml of each sample was loaded onto a Superose 6 10/300 GL column (GE Healthcare) pre-equilibrated with 25 mM Tris (pH 7.5), 150 mM NaCl, 5% Glycerol, 2 mM DTT and 40 mM ZnSO 4 and resolved at a flow rate of 0.5 ml/min on an AkTA (GE Healthcare) automated liquid chromatography system. Size fractions of 0.5 ml were collected and an equal volume aliquot of each fraction was analyzed by western blotting using relevant antibodies indicated in the respective figures.
Gel-Shift Assay and IKK Kinase Assay
Gel-shift assays were performed as previously described (Basak et al., 2007) . Briefly, nuclear extracts were incubated with 32 P-labeled 38 bp spanning double-stranded oligonucleotides containing two consensus kB sites at room temperature for 20 min prior to complex separation on a nondenaturing acrylamide gel. Bands were visualized by autoradiography and quantified using ImageQuant software. In vitro IKK kinase assays were performed as described previously (Werner et al., 2005) . The IKK complex was immunoprecipitated from cytoplasmic extracts using a NEMO-specific antibody (BD or Santa Cruz Biotechnology) and Protein A-sepharose beads. In NEMOdeficient cells, IKK kinase complexes were precipitated using an IKKa antibody (Santa Cruz Biotechnology) or HA antibody (Covance) to pull down HA-tagged IKKb. Beads were subjected to in vitro kinase reaction containing 32 P-ATP and 1 mg GST-IkBa 1-54 , GST-IkBa 1-54 D27/28R, full-length wild-type or D27/28R His-IkBa, full-length p105 or GST-p65 AD as substrates. For competitor experiments 10 mg BSA and 50 ng of substrate and indicated amounts of recombinant wild-type or 1-319 hNEMO were added to the kinase reaction. Upon incubation at 30 C for indicated time, reactions were stopped by boiling samples in SDS sample buffer. Proteins were resolved by SDS-PAGE and visualized by autoradiography or western blotting.
Coimmunoprecipitation and Western Blotting
For western blot analysis, whole-cell extracts were prepared using RIPA buffer supplemented with PMSF, DTT, and phosphatase inhibitors. Samples were normalized for equal amounts of proteins using a Bradford assay (Biorad). Phospho-specific antibodies to IkBa (S32/36) p65 (S536), p105 (S933), p-AMPK (T172) and AMPK, p-p70 S6 Kinase (T389), and p70 S6 Kinase were from Cell Signaling. For coimmunoprecipitation experiments, 293T cells were transfected with indicated amounts of pcMyc-NEMO, pcFLAG-IkBa, and pcHA-IKKb or empty vector. Total amounts of DNA used for transfections were normalized with empty vector. Cells were lysed in buffer containing 10 mM HEPES-KOH (pH 7.9), 250 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.2% Tween 20, 1 mM DTT, 1 mM PMSF, and 10 mM MG132. Lysates were precleared with protein A/G sepharose beads followed by immunoprecipitation with anti-Myc (Roche), anti-HA (Covance) or anti-FLAG (Sigma) antibody for 2 hr. Complexes were collected by addition of 10 ml protein A/G Sepharose for 2 hr followed by extensive washing in lysis buffer at 37 C. Samples were analyzed on immunoblots probed with indicated antibodies.
Microscopy
Cells were grown on poly-L lysine-coated glass coverslips and where indicated treated with HBSS for starvation. Cells were fixed with 4% formaldehyde for 15 min, incubated with methanol at À20 C for 10 min followed by blocking with 10% normal goat serum for 1 hr. Anti-LC3A/B antibody (Cell Signaling) was used for scoring cells undergoing autophagy. Goat-anti-rabbit Alexa Fluor 488 (Invitrogen) was used as secondary antibody. Nuclei were counterstained with Hoechst. Images were taken on a Zeiss Axio Observer Z1 microscope. For quantification, at least 50 cells were counted in three independent experiments. Statistical significance was tested using two-sided student's t test.
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